- Home
- ABEO vs AVTX Comparison
ABEO vs AVTX Comparison
Compare ABEO & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABEO | AVTX |
|---|---|---|
| Founded | 1974 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.5M | 328.4M |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ABEO | AVTX |
|---|---|---|
| Price | $5.49 | $17.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $20.00 | ★ $40.57 |
| AVG Volume (30 Days) | 1.0M | ★ 2.0M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | $2,998,000.00 | ★ $27,813,137.00 |
| Revenue This Year | $1,024.31 | N/A |
| Revenue Next Year | $145.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 258.18 | ★ 2312.27 |
| 52 Week Low | $4.00 | $3.43 |
| 52 Week High | $7.54 | $24.27 |
Technical Indicators
Market Signals| Indicator | ABEO | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 52.60 |
| Support Level | $5.24 | $13.47 |
| Resistance Level | $5.54 | $19.39 |
| Average True Range (ATR) | 0.27 | 1.90 |
| MACD | -0.04 | 0.24 |
| Stochastic Oscillator | 35.50 | 42.94 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.